J Korean Ophthalmol Soc.  2003 May;44(5):1085-1092.

Inhibition of Melanoma Cell Lines Using Antisense Sequence Expressing Adenovirus and Cisplatin

Affiliations
  • 1Kim In-Sook Eye Clinic, Korea.
  • 2Institute of Biotechnology, Korea University, Korea.
  • 3Department of Obstetrics and Gynecology, Korea University College of Medicine, Korea.
  • 4Department of Ophthalmology, Korea University College of Medicine, Korea. junghr@korea.ac.kr

Abstract

PURPOSE
Telomerase is known to play a role of adding repetitive parts to chromosomal ending and to be involved in carcinogenic process through cell immortalization. The purpose of this study is to evaluate that restraining of telomerase activation can have killing effect on cancer cell and enhance susceptibility of cancer cells to anticancer substance. METHODS: The killing effect on melanoma cells was studied by using recombinant adenovirus that makes it possible to inhibit telomerase from getting activated, with such targets as two types of melanoma cell lines. This recombinant adenovirus was used combined with cisplatin, one of the most representative anticancer medicine to evaluate enhancement in susceptibility of cancer cells to anticancer substance. RESULTS: From the result of cytotoxic assay, it is found that melanoma cells have much resistance to cisplatin on the whole. In the case of using Ad-OA of recombinant virus alone, killing effect on melanoma cells was insignificant. On the other hand, when Ad-OA was used in combination with cisplatin, susceptibility of melanoma cell lines to cisplatin was enhanced. CONCLUSIONS: Ad-OA, recombinant adenovirus, could be used as a supplementary medicine in the targeted cancer gene therapy against cancer cell lines resistant to cisplatin.

Keyword

Telomerase; Melanoma; Adenovirus; Cisplatin; Targeted cancer gene therapy

MeSH Terms

Adenoviridae*
Cell Line*
Cisplatin*
Genes, Neoplasm
Hand
Homicide
Melanoma*
Telomerase
Cisplatin
Telomerase
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr